Literature DB >> 21868487

Clinical scales in progressive MS: predicting long-term disability.

Libertje V A E Bosma1, Jolijn J Kragt, Dirk L Knol, Chris H Polman, Bernard M J Uitdehaag.   

Abstract

BACKGROUND: To determine which short-term changes on clinical scales including the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg test (9HPT) and Guy's Neurological Disability Scale (GNDS) are most predictive of long-term outcome of disability as rated by the EDSS in progressive multiple sclerosis (MS).
METHODS: From a longitudinal database, all progressive patients, both primary (PP) and secondary (SP), were selected on the basis of at least two complete examinations being available within a time interval of 1-2 years (short-term change). All patients who fulfilled the selection criteria were invited for a third visit after an interval of at least 3 years (long-term outcome). We used ordinal logistic regression to see which early changes were most predictive of the long-term EDSS.
RESULTS: 181 patients fulfilled the selection criteria. Early change on EDSS and T25FW were the best predictors of long-term EDSS; both were significant predictors in a 'single predictor' model. Early EDSS change was a slightly stronger single predictor (R(2) 0.38, Wald χ(2) 42.65, p < 0.001) compared with early T25FW change (R(2) 0.27, Wald χ(2) 12.35, p < 0.001). Adding early T25FW change to early EDSS change in a 'combined predictor' model improved prediction (p = 0.036).
CONCLUSION: Both early change on EDSS and T25FW predict long-term EDSS with comparable strength. Early change on T25FW adds significant independent information and improves the prediction model with early EDSS change only. Therefore we support the use of early T25FW examinations in future clinical trials in progressive MS.

Entities:  

Mesh:

Year:  2011        PMID: 21868487     DOI: 10.1177/1352458511419880

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  8 in total

1.  Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.

Authors:  Myla D Goldman; Robert W Motl; John Scagnelli; John H Pula; Jacob J Sosnoff; Diego Cadavid
Journal:  Neurology       Date:  2013-10-30       Impact factor: 9.910

Review 2.  Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.

Authors:  Jan-Patrick Stellmann; Anneke Neuhaus; Christian Lederer; Martin Daumer; Christoph Heesen
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

3.  Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.

Authors:  Marcus W Koch; Gary R Cutter; Gavin Giovannoni; Bernard M J Uitdehaag; Jerry S Wolinsky; Mat D Davis; Joshua R Steinerman; Volker Knappertz
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-05-10

4.  Exploration of machine learning techniques in predicting multiple sclerosis disease course.

Authors:  Yijun Zhao; Brian C Healy; Dalia Rotstein; Charles R G Guttmann; Rohit Bakshi; Howard L Weiner; Carla E Brodley; Tanuja Chitnis
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

5.  Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge.

Authors:  Karine Baumstarck; Laurent Boyer; Mohamed Boucekine; Pierre Michel; Jean Pelletier; Pascal Auquier
Journal:  Mult Scler Int       Date:  2013-02-28

6.  Targeting thalamic tremor cells in deep brain stimulation for multiple sclerosis-induced complex tremor.

Authors:  Ersoy Kocabicak; Murat Terzi; Onur Alptekin; Yasin Temel
Journal:  Surg Neurol Int       Date:  2013-03-22

7.  Opposite roles of NMDA receptors in relapsing and primary progressive multiple sclerosis.

Authors:  Silvia Rossi; Valeria Studer; Alessandro Moscatelli; Caterina Motta; Giancarlo Coghe; Giuseppe Fenu; Stacy Caillier; Fabio Buttari; Francesco Mori; Francesca Barbieri; Maura Castelli; Valentina De Chiara; Fabrizia Monteleone; Raffaele Mancino; Giorgio Bernardi; Sergio E Baranzini; Maria G Marrosu; Jorge R Oksenberg; Diego Centonze
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

Review 8.  Measuring Treatment Response in Progressive Multiple Sclerosis-Considerations for Adapting to an Era of Multiple Treatment Options.

Authors:  Nik Krajnc; Thomas Berger; Gabriel Bsteh
Journal:  Biomolecules       Date:  2021-09-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.